Estimation of Baseline Dopamine D2 Receptor Occupancy in Striatum and Extrastriatal Regions in Humans with Positron Emission Tomography with [18F] Fallypride

[1]  R. Narendran,et al.  Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]‐(+)‐PHNO is a D3 receptor preferring agonist in vivo , 2006, Synapse.

[2]  Benoit Dawant,et al.  Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine , 2006, Neuropsychopharmacology.

[3]  Hans-Georg Buchholz,et al.  The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia , 2006, Neuropsychopharmacology.

[4]  Mohammad Sib Ansari,et al.  Amphetamine-Induced Displacement of [18F] Fallypride in Striatum and Extrastriatal Regions in Humans , 2006, Neuropsychopharmacology.

[5]  Paul Cumming,et al.  Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Mark Slifstein,et al.  Effect of amphetamine on [18F]fallypride in vivo binding to D2 receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies , 2004, Synapse.

[7]  F. Yasuno,et al.  Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. , 2004, The American journal of psychiatry.

[8]  Benoit M. Dawant,et al.  The adaptive bases algorithm for intensity-based nonrigid image registration , 2003, IEEE Transactions on Medical Imaging.

[9]  S. Kapur,et al.  In vivo evidence for dopamine-mediated internalization of D2-receptors after amphetamine: differential findings with [3H]raclopride versus [3H]spiperone. , 2003, Molecular pharmacology.

[10]  G. Gerhardt,et al.  Changes in somatodendritic but not terminal dopamine
regulation in aged rhesus monkeys , 2002, Journal of neurochemistry.

[11]  J Tauscher,et al.  Dopamine depletion results in increased neostriatal D2, but not D1, receptor binding in humans , 2002, Molecular Psychiatry.

[12]  M. Egan,et al.  Prefrontal neurons and the genetics of schizophrenia , 2001, Biological Psychiatry.

[13]  Shitij Kapur,et al.  A Simple Method to Measure Baseline Occupancy of Neostriatal Dopamine D2 Receptors by Dopamine In Vivo in Healthy Subjects , 2001, Neuropsychopharmacology.

[14]  Max A. Viergever,et al.  Mutual information matching in multiresolution contexts , 2001, Image Vis. Comput..

[15]  R. V. Van Heertum,et al.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Kapur,et al.  Schizophrenia: more dopamine, more D2 receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M Fujita,et al.  Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. , 2000, European journal of pharmacology.

[18]  P. Sokoloff,et al.  Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. , 1999, European journal of pharmacology.

[19]  G. Gerhardt,et al.  GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys , 1999, Brain Research.

[20]  J. Joyce,et al.  Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain: Comparison with D2 Receptor Expressing Neurons , 1999, Neuropsychopharmacology.

[21]  P S Goldman-Rakic,et al.  Prominence of the dopamine D2 short isoform in dopaminergic pathways. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Goldman-Rakic.  The cortical dopamine system: role in memory and cognition. , 1998, Advances in pharmacology.

[23]  L. Seiden,et al.  Evaluation of d‐amphetamine effects on the binding of dopamine D‐2 receptor radioligand, 18F‐fallypride in nonhuman primates using positron emission tomography , 1997, Synapse.

[24]  Marc Laruelle,et al.  Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.

[25]  S. Cragg,et al.  Differential Autoreceptor Control of Somatodendritic and Axon Terminal Dopamine Release in Substantia Nigra, Ventral Tegmental Area, and Striatum , 1997, The Journal of Neuroscience.

[26]  D J Brooks,et al.  Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  J. Wamsley,et al.  Time dependent changes in DA uptake sites, D1 and D2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain , 1995, Journal of Chemical Neuroanatomy.

[28]  Jonathan D. Cohen,et al.  Improved Assessment of Significant Activation in Functional Magnetic Resonance Imaging (fMRI): Use of a Cluster‐Size Threshold , 1995, Magnetic resonance in medicine.

[29]  S. Sesack,et al.  Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[30]  J R Votaw,et al.  Visualization of extrastriatal dopamine D2 receptors in the human brain. , 1992, European journal of pharmacology.

[31]  R. Murray,et al.  A developmental perspective on the pathology and neurochemistry of the temporal lobe in schizophrenia , 1992, Schizophrenia Research.